scholarly journals Nutritional Risk Screening and Assessment

2019 ◽  
Vol 8 (7) ◽  
pp. 1065 ◽  
Author(s):  
Emilie Reber ◽  
Filomena Gomes ◽  
Maria F. Vasiloglou ◽  
Philipp Schuetz ◽  
Zeno Stanga
Keyword(s):  
Quality Of Life ◽  
At Risk ◽  
Nutritional Support ◽  
Nutritional Risk ◽  
Nutritional Management ◽  
Risk Screening ◽  
Care Plans ◽  
Patients At Risk ◽  
Nutritional Risk Screening

Malnutrition is an independent risk factor that negatively influences patients’ clinical outcomes, quality of life, body function, and autonomy. Early identification of patients at risk of malnutrition or who are malnourished is crucial in order to start a timely and adequate nutritional support. Nutritional risk screening, a simple and rapid first-line tool to detect patients at risk of malnutrition, should be performed systematically in patients at hospital admission. Patients with nutritional risk should subsequently undergo a more detailed nutritional assessment to identify and quantify specific nutritional problems. Such an assessment includes subjective and objective parameters such as medical history, current and past dietary intake (including energy and protein balance), physical examination and anthropometric measurements, functional and mental assessment, quality of life, medications, and laboratory values. Nutritional care plans should be developed in a multidisciplinary approach, and implemented to maintain and improve patients’ nutritional condition. Standardized nutritional management including systematic risk screening and assessment may also contribute to reduced healthcare costs. Adequate and timely implementation of nutritional support has been linked with favorable outcomes such as a decrease in length of hospital stay, reduced mortality, and reductions in the rate of severe complications, as well as improvements in quality of life and functional status. The aim of this review article is to provide a comprehensive overview of nutritional screening and assessment methods that can contribute to an effective and well-structured nutritional management (process cascade) of hospitalized patients.

scholarly journals Predictors of Health-Related Quality of Life in Patients at Risk for Cardiovascular Disease in European Primary Care

PLoS ONE ◽  
2011 ◽  
Vol 6 (12) ◽  
pp. e29334 ◽  
Author(s):  
Sabine Ludt ◽  
Michel Wensing ◽  
Joachim Szecsenyi ◽  
Jan van Lieshout ◽  
Justine Rochon ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cardiovascular Disease ◽  
Primary Care ◽  
At Risk ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Patients At Risk

Identifying COPD patients at risk for worse symptoms, quality of life and self-efficacy: A cluster analysis

2017 ◽  
Author(s):  
Aline Costa Lopes ◽  
Celso Carvalho ◽  
Rafaella Fagundes Xavier ◽  
Ana Carolina Alves Caporali ◽  
Rafael Stelmach ◽  
...  
Keyword(s):  
Quality Of Life ◽  
At Risk ◽  
Cluster Analysis ◽  
Self Efficacy ◽  
Copd Patients ◽  
Patients At Risk

WC3C PROBABLY PRODROMAL, BUT CERTAINLY ILL: QUALITY OF LIFE AND SOCIAL ADJUSTMENT IN PATIENTS AT RISK OF PSYCHOSIS. RESULTS OF THE EPOS STUDY

2006 ◽  
Vol 86 ◽  
pp. S9
Author(s):  
R.K.R. Salokangas ◽  
M. Heinimaa ◽  
J. Klosterkötter ◽  
S. Ruhrmann ◽  
H. Graf von Reventlow ◽  
...  
Keyword(s):  
Quality Of Life ◽  
At Risk ◽  
Social Adjustment ◽  
Patients At Risk

scholarly journals Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life

2021 ◽  
Vol 8 (1) ◽  
pp. 234-247
Author(s):  
Alexander D. Sherry ◽  
Dario Pasalic ◽  
G. Brandon Gunn ◽  
C. David Fuller ◽  
Jack Phan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
At Risk ◽  
Head And Neck ◽  
Head And Neck Carcinoma ◽  
Unknown Primary ◽  
Carcinoma Of Unknown Primary ◽  
Neck Carcinoma ◽  
Patients At Risk ◽  
Md Anderson

Abstract Purpose Proton radiation therapy (PRT) may offer dosimetric and clinical benefit in the treatment of head and neck carcinoma of unknown primary (HNCUP). We sought to describe toxicity and quality of life (QOL) in patients with HNCUP treated with PRT. Patients and Methods Toxicity and QOL were prospectively tracked in patients with HNCUP from 2011 to 2019 after institutional review board approval. Patients received PRT to the mucosa of the nasopharynx, oropharynx, and bilateral cervical lymph nodes with sparing of the larynx and hypopharynx. Patient-reported outcomes were tracked with the MD Anderson Symptom Inventory–Head and Neck Module, the Functional Assessment of Cancer Therapy–Head and Neck, the MD Anderson Dysphagia Inventory, and the Xerostomia-Related QOL Scale. Primary study endpoints were the incidence of grade ≥ 3 (G3) toxicity and QOL patterns. Results Fourteen patients (median follow-up, 2 years) were evaluated. Most patients presented with human papillomavirus–positive disease (n = 12, 86%). Rates of G3 oral mucositis, xerostomia, and dermatitis were 7% (n = 1), 21% (n = 3), and 36% (n = 5), respectively. None required a gastrostomy. During PRT, QOL was reduced relative to baseline and recovered shortly after PRT. At 2 years after PRT, the local regional control, disease-free survival, and overall survival were 100% (among 7 patients at risk), 79% (among 6 patients at risk), and 90% (among 7 patients at risk), respectively. Conclusion Therefore, PRT for HNCUP was associated with highly favorable dosimetric and clinical outcomes, including minimal oral mucositis, xerostomia, and dysphagia. Toxicity and QOL may be superior with PRT compared with conventional radiation therapy and PRT maintains equivalent oncologic control. Further prospective studies are needed to evaluate late effects and cost-effectiveness.

scholarly journals A Review of Cisplatin-Associated Ototoxicity

2019 ◽  
Vol 40 (02) ◽  
pp. 108-121 ◽  
Author(s):  
Jessica Paken ◽  
Cyril Govender ◽  
Mershen Pillay ◽  
Vikash Sewram
Keyword(s):  
Quality Of Life ◽  
Risk Factors ◽  
At Risk ◽  
Health Care Professionals ◽  
Monitoring Program ◽  
Clinical Signs ◽  
Incidence Rates ◽  
Cellular Mechanisms ◽  
Patients At Risk

AbstractCisplatin, an effective antineoplastic drug used in the treatment of many cancers, has ototoxic potential, thus placing cancer patients, receiving this treatment, at risk of hearing loss. It is therefore important for health care professionals managing these patients to be aware of cisplatin's ototoxic properties and its clinical signs to identify patients at risk of developing a hearing impairment. Eighty-five English peer-reviewed articles and two books, from January 1975 to July 2015, were identified from PubMed, ScienceDirect, and EBSCOhost. An overview of cisplatin-associated ototoxicity, namely its clinical features, incidence rates, molecular and cellular mechanisms, and risk factors, is presented in this article. This review further highlights the importance of a team-based approach to complement an audiological monitoring program in reducing any further loss in the quality of life of affected patients, as there is currently no otoprotective agent routinely recommended for the prevention of cisplatin-associated ototoxicity.

Subjective quality of life and its changes in patients at-risk for psychosis results of the EPOS study

2011 ◽  
Vol 26 (S2) ◽  
pp. 2039-2039
Author(s):  
R. Salokangas ◽  
T. Svirskis ◽  
M. Heinimaa ◽  
J. Klosterkötter ◽  
S. Ruhrmann ◽  
...  
Keyword(s):  
Quality Of Life ◽  
At Risk ◽  
Depressive Disorders ◽  
Familial Risk ◽  
Young Patients ◽  
Point Of View ◽  
Psychotic Symptoms ◽  
Subjective Quality Of Life ◽  
Patients At Risk

ObjectivesIn the European Prediction of Psychosis Study (EPOS) a large sample of young patients at high risk of psychosis (HR) were examined and their conversion rate to psychosis during 18 months follow-up was estimated. This presentation describes quality of life (QoL) and its changes in patients at risk of psychosis who did or did not convert to psychosis.MethodsIn all, 245 young HR patients were recruited and followed for 9 and 18 months. Risk of psychosis was defined by occurrence of basic symptoms (BS), attenuated psychotic symptoms (ATP), brief, limited or intermittent psychotic symptoms (BLIPS) or familial risk plus reduced functioning (FR-RF). QoL was assessed at baseline and at 9 and 18 months’ follow-ups, and analysed in the HR-patients who converted (HR-P; n = 40) or did not converted to psychosis (HR-NP; n = 205).ResultsThere were no differences in the course of QoL between the HR-P and HR-NP patients. Of the inclusion criteria, only BS associated with poor QoL at baseline. Among HR-NP subjects, depressive symptoms associated with QoL at baseline and predicted poor QoL at 9 and 18 month follow-ups.ConclusionsQoL of the HR-NP patients is as poor as that of the HR-P. From the QoL point of view, all HR patients require intensive treatment intervention from the first contact on. Especially, depressive disorders need to be treated vigorously.

Sign in / Sign up

Export Citation Format

Share Document